Navigation Links
Xanodyne Raises $50 Million in Equity Financing to Support Emerging Product Portfolio
Date:10/29/2009

NEWPORT, Ky., Oct. 29 /PRNewswire/ -- Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management, announced today the completion of $50 million in equity financing. The round was led by Longitude Capital with participation from new investors Skandia and Silver Point Capital. Other current investors that participated in the financing include MPM Capital, LLC, AIG Investments' sponsored funds, Perseus-Soros Biopharmaceutical Fund, Blue Chip Venture Company, HealthCare Ventures, LLC, and Union Springs, LLC. Aquilo Partners, L.P., a life science investment bank, acted as the exclusive placement agent for the financing.

Michael J. Valentino, President and CEO commented, "I am extremely pleased to have secured additional financial resources which will be used to support our ongoing development and commercialization strategy for our emerging product portfolio."

In June 2009, Xanodyne received Food and Drug Administration (FDA) approval for Zipsor(TM) (diclofenac potassium) Liquid Filled Capsules, a new treatment option for relief of mild to moderate acute pain in adults (18 years of age or older). Zipsor was launched nationally to physicians and patients in September.

In addition, the company expects FDA action soon on Lysteda(TM) (formerly XP12B), an oral tranexamic acid product under priority review. If approved, Lysteda would be the first and only oral therapeutic agent indicated specifically for the treatment of women suffering from cyclic heavy menstrual bleeding.

Valentino added, "The continued commitment from our investor groups allows us to remain focused on aggressively executing our product commercialization plans and optimizing the other assets in our portfolio."

About Xanodyne

Xanodyne Pharmaceuticals, Inc., which commenced operations in 2001, is an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management. Xanodyne markets a portfolio of products consisting of prescription pharmaceuticals and a line of prenatal vitamins. Additionally, Xanodyne is advancing a late stage pipeline of product candidates targeted at significant potential markets in Xanodyne's focus areas.

SOURCE Xanodyne Pharmaceuticals, Inc.


'/>"/>
SOURCE Xanodyne Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Globus Medical Raises $110 Million in Series E Financing Round
2. EntreMed Raises $20 Million to Support Clinical Development Program
3. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
4. Romark Laboratories Raises $18 Million in Institutional Financing
5. Light Sciences Oncology Raises $40.1 Million in Series C Financing
6. Celator Pharmaceuticals Raises Series C Financing in Excess of $22.5 Million
7. ESBATech Raises Additional CHF 23M (USD 22M), Extending Series B Venture Financing
8. Ironwood Raises $50 Million to Advance Linaclotide Through Phase 3
9. Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million
10. Cardio3 BioSciences Raises EUR13.7 Million in Series B Fundraising and Grant Funding
11. SynergEyes, Inc. Raises $13.3 Million in Series C Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... -- Summary Breast cancer, a malignant neoplasm, is ... cancer in women worldwide, accounting for 16% of all ... of women diagnosed with breast cancer has increased over ... has declined due to earlier diagnosis and better treatment ... the past four decades, especially with increasing usage of ...
(Date:2/4/2016)... MOUNTAIN VIEW, Calif., Feb. 4, 2016  Omnicell, Inc. (NASDAQ: ... supply management solutions to healthcare systems, today announced results ... 2015.  --> --> ... was $130.3 million, up $5.1 million or 4.1% from ... or 7.2% from the fourth quarter of 2014. Revenue ...
(Date:2/4/2016)... , Feb. 4, 2016 In response to the ... FDA,s Deputy Commissioner for Medical Products and Tobacco, along with ... reassess the agency,s approach to opioid medications. The plan will ... providing patients in pain access to effective relief. ... , Re-examine the risk-benefit paradigm for opioids and ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... Love is in the air at ... of colors, assortments and packaging. This staple for Valentine’s Day is a must-have, and ... , For Valentine’s Day, not only are long-stem roses available, but also other flower ...
(Date:2/5/2016)... ... February 05, 2016 , ... The Muscular Dystrophy Association and ... launched the 14th annual “Appetite for a Cure” campaign on Feb. 1 to ... and related diseases that severely limit strength and mobility. , Now through ...
(Date:2/5/2016)... ... February 05, 2016 , ... The ... funding innovative lymphoma research and serving the lymphoma community through a comprehensive series ... again host, Swirl, A Wine Tasting Event at the La Gorce Country Club ...
(Date:2/5/2016)... Dallas, Texas (PRWEB) , ... February 05, 2016 , ... ... to allow users to search for and donate to Give To Cure’s campaign ... is an app that lets users make and share payments through a smart device. ...
(Date:2/5/2016)... MA (PRWEB) , ... February 05, 2016 , ... ... in tattoo technology, the PicoSure. Designed to provide the most effective tattoo removal today, ... option with unmatched results. , Developed by Cynosure, the PicoSure has been approved by ...
Breaking Medicine News(10 mins):